A reprocessing instruction is not a description of what a clinic usually does; it is a claim that a manufacturer has tested a specific sequence and can prove the result. AAMI TIR12 tells a device maker how to design and test that sequence and what the instruction has to say, while AAMI TIR31 covers the process challenge devices that make the sterilization part of the claim testable. This guide reads the two documents together, then adds the Canadian layer that turns the output into a legal obligation, so that a clinic buyer can tell a validated instruction from a well-formatted wish.
Everything below is written for the person who receives the instruction and has to defend it in an inspection. Where the article names a product, it is because that product sits inside one of the validated steps, not because it is the subject: the packaging side of the chain is described through a
sterilization pouch with dual indicators, and the log side through the compliance log centre, which holds the printable cycle and release records. The clinic-facing half of the same standard is set out separately in what ISO 17664 obliges a clinic to keep.
Quick facts
- AAMI TIR12:2020/(R)2023 is titled Designing, testing, and labeling medical devices intended for processing by health care facilities: A guide for device manufacturers. It was reaffirmed in 2023.
- The 2010 edition of the same report was titled Designing, testing and labeling reusable medical devices for reprocessing in health care facilities; the 2020 rewrite dropped "reusable" and moved the scope to devices a health care facility processes before clinical use.
- A technical information report is not a standard. AAMI describes the document class as approved for distribution by a technical committee and by the AAMI Standards Board, without the formal consensus approval process a standard goes through.
- AAMI TIR31:2008 is 46 pages and exists to help health care facilities select and use process challenge devices; its keyword list covers biological indicators, chemical indicators, steam, dry heat, ethylene oxide, vaporized hydrogen peroxide and steam sterilization in tabletop units.
- ISO 17664-1:2021 sets the requirement that anchors the whole file: the manufacturer shall validate each process that is identified in the information supplied with the device.
- In Canada, the instruction is a labelling obligation, not a courtesy: paragraph 21(1)(i) of the Medical Devices Regulations requires directions for use unless they are not needed for safe and effective use.
What does AAMI TIR12 cover, and what changed in the 2020 edition?
TIR12 is written for the manufacturer, and its subject is the handover between two organisations. A device maker knows how the device is built; a reprocessing department knows what its equipment, chemistry and staffing can actually deliver. TIR12 sits in that gap and gives the manufacturer a method for defining the processing steps from pre-treatment at the point of use, through the terminal process and storage, and for stating them in a way a facility can follow. It also sets out what the facility side of the handover looks like, which is why the report is useful to a clinic that wants to read an instruction critically rather than passively.
Two changes in the 2020 rewrite matter at the bench. The first is scope: the earlier title addressed reusable devices, while the current text addresses medical devices intended for processing by a health care facility, including single-use devices that a facility processes before clinical use. That shift is not permission to reprocess single-use devices in Canada. Provincial guidance is explicit that health care settings must not internally reprocess single-use equipment and devices, and that critical or semi-critical devices labelled single-use must not be reprocessed unless a licensed reprocessor does the work, while noting that there are currently no licensed reprocessors in Canada. The TIR12 scope change matters because device makers now write processing information for devices that cross that boundary in other jurisdictions, and because a Canadian buyer may be shown such an instruction by a supplier who has not checked which side of the line the device sits on.
The second change is structural: the current report treats risk management as the spine of the exercise rather than a preface. AAMI's own summary of the report quotes its definition of risk management as a closed-loop process of identifying potential or known risks, evaluating probability and severity, applying controls, then monitoring those controls and feeding the results back into the system. For a reprocessing instruction, that loop is what separates a parameter from a validated parameter. A temperature is a number; a validated temperature is a number with a stated worst case, a stated soil, a stated load and a record that shows the result was monitored.
TIR12 also states the purpose of processing in three objectives that read as a specification for the instruction itself: render the device safe to handle, prepare it for the next processing step, and make it ready for the next patient. An instruction that satisfies only the third objective, by describing a sterilization cycle and nothing else, leaves the two steps where most failures actually occur undescribed.
Where does AAMI TIR31 fit, and where does it stop?
TIR31 is often misread as a companion volume on how to test a reprocessing instruction. It is not. Its stated purpose is to help health care facilities select and use process challenge devices, and its audience is the facility, not the device manufacturer. A process challenge device is the object that places a defined resistance in the path of the sterilant, so that a passing result means the process penetrated something harder than an empty chamber. TIR31 is the document that tells a facility what kinds of challenge device exist, what each one is for by sterilization modality, and how to choose among them.
That makes TIR31 the bridge between TIR12's claim and the facility's evidence. The manufacturer validates a cycle and states the load configuration and the challenge it used; the facility then runs routine monitoring with a challenge device appropriate to that cycle. When the two are chosen independently, the monitoring can pass while proving less than the validation claimed. The practical question to ask a supplier is therefore not "is your cycle validated" but "which challenge device was used in the performance qualification, and is the device we run daily built to the same resistance".
The limits are worth stating plainly. TIR31 does not tell a manufacturer what its instruction must contain, it does not set acceptance criteria for cleaning, and it does not replace the sterilizer standards that govern the cycle itself. It covers the challenge side of sterilization monitoring, across several modalities, and nothing else.
What has to be validated at each step, and what does the instruction have to say?
The table below is the working core of this article. Read the four columns left to right: the step, the claim that has to be tested, the sentence the instruction owes the user, and the document that should exist in the manufacturer's file if the sentence is true. Nothing in the table is a parameter value; those come from the validated instruction itself and from the current edition of the applicable standard.
| Step | What must be validated | What the instruction must state | What the evidence file should hold |
|---|---|---|---|
| Point-of-use preparation and transport | That the stated pre-treatment keeps soil from drying beyond the cleaning method's capability, including the longest delay the instruction permits | Containment, pre-treatment steps, maximum time before cleaning, temperature limits during transport | Soil-drying or delay study at the stated worst case, with the cleaning method that follows |
| Cleaning, manual or automated | That the method removes the test soil from the hardest-to-reach feature at the stated parameters | Method, chemistry family and concentration, temperature, time, water quality, loading orientation | Cleaning validation report with test soil, extraction or detection method, and acceptance rationale |
| Disinfection | That the chemistry and contact time achieve the intended level on this device, and that the device survives repeated exposure | Validated disinfectant types, at least one example trade name, concentration, temperature, contact time, maximum cycles | Disinfection efficacy data plus material compatibility and repeated-exposure data |
| Drying | That the stated method and duration leave the device dry enough for packaging and sterilization | Drying method, duration, and any lumen or hinge requirement | Drying verification, including the worst-case geometry |
| Inspection, maintenance and testing | That the stated function tests detect the failures the instruction says to look for | Test steps, acceptance criteria, rejection and repair route | Functional test protocol with sensitivity data for the failure modes named |
| Packaging | That the stated packaging and configuration maintain a sterile barrier through handling, sterilization and storage | Pouch or container type, weight and density limits, configuration, sealing method | Packaging validation to the ISO 11607 series, including seal strength and ageing |
| Sterilization | That the stated cycle achieves the claimed sterility assurance level on this load, in that configuration, with that challenge | Method, cycle type, temperature, exposure and drying times, load pattern, challenge device used | Performance qualification with biological and chemical indicators, plus the physical data behind it |
| Storage and shelf life | That the labelled storage conditions and shelf life keep the barrier intact | Storage conditions, maximum shelf life, handling limits | Ageing and stability study, event-related or date-related rationale |
| Reuse limitation | That the device still meets its specification at the last permitted cycle | Maximum number of reprocessing cycles, and how the user tracks them | Cycle-limit testing, plus the marking or tracking method the instruction requires |
Two rows are routinely thin in real instructions, and both are visible from the clinic side. Drying is often given as a line in a cycle description rather than as a step with its own duration and geometry caveat. Reuse limitation is often expressed as "single patient use" or "reusable" without a number, which pushes the tracking obligation onto the facility with no criterion to track against. In Canada, the 2011 health Canada guidance on reprocessing information addresses the second point directly: a reusable device that the manufacturer designates for a specific number of cycles should, where feasible, carry an identifier unique to that individual device so the user can track the count or know when it will no longer safely fulfil its intended use.
How do those steps become an evidence file?
The file is smaller than the table suggests, because several rows share one report. A practical structure has five documents: a risk analysis under ISO 14971 that names the processing hazards and the controls that address them; one validation report per process family, covering cleaning, disinfection, drying and sterilization as the risk analysis scoped them; a packaging validation; a compatibility and cycle-limit file; and a labelling rationale that maps each statement in the instruction to the report that supports it. The last document is the one auditors ask for first, because it converts a library into a traceable chain.
Grouping is permitted, with a condition. Health Canada's 2011 guidance allows groups of similar devices to share the same validation, provided the reprocessing procedures are the same for all devices in the group, and the same logic applies to shared instructions as long as an identifier such as a catalogue number appears in the instructions and, where possible, on the device. The condition is the whole point: a family claim is only as good as the demonstration that the family is genuinely one family.
A supplier who cannot produce the labelling rationale can still be a legitimate supplier, but the buyer should stop treating the instruction as validated. The distinction matters at the point of purchase, because the same document is used two ways: the clinic follows it, and the inspector tests the clinic against it.
What must the instruction actually contain?
The field list is not arbitrary. ISO 17664-1:2021 structures the information for critical and semi-critical devices around a sequence that maps almost one to one onto the rows above: preparation at the point of use, preparation and cleaning, disinfection, drying, inspection and maintenance, packaging, sterilization, storage, and any limitation on reuse. Part 2 of the same standard covers non-critical devices. The requirement that gives the sequence force is short: the manufacturer shall validate each process that is identified in the information supplied with the device, and the validation must rest on objective evidence rather than on general experience.
Health Canada's 2011 guidance adds the details that Canadian buyers most often find missing, and it is worth quoting the categories rather than paraphrasing them into advice. On request from the purchaser, the manufacturer or importer should provide the names of suppliers of equipment and tools, and the trade name of at least one example of each cleaning agent, disinfectant, sterilant or other product needed for reprocessing and testing that the manufacturer has validated as acceptable; a summary of the validation procedures confirming that the specific device will be clean and sterile when reprocessed as directed; and, where the device is sold in a container in which it is to be sterilized, a summary of the validation for sterilizing it in that container.
The guidance also sets expectations for the instructions themselves: disassembly and reassembly should be shown with photographs or schematic diagrams and a list of components; instructions should be specific to the device, with an identifier such as a catalogue number; sterilization instructions should specify the method, process temperatures and times, and drying or aeration times; and the instructions should account for equipment usually available in a health care facility and the times and temperatures commonly used in North America. There is also a field most instructions never carry: any special storage conditions applicable to the device, which the Regulations require as label content in their own right.
Which Canadian requirements turn those fields into obligations?
Three layers stack here, and each one binds a different party.
The first is the regulation. Section 21 of the Medical Devices Regulations prohibits importing or selling a device unless the label sets out the directions for use, unless directions are not required for the device to be used safely and effectively, and unless it sets out any special storage conditions; the information must be expressed in a legible, permanent and prominent manner in terms the intended user can understand. Section 23 sets the language floor: information must be at least in English or French, and where directions for use are supplied in only one official language at the time of sale, the manufacturer must make them available in the other official language as soon as possible at the purchaser's request. For a device sold to the general public, the listed label items must appear in both languages.
The second layer is the licensing file. A Class II licence application must include an attestation by a senior official that the device meets the applicable labelling requirements, under paragraph 32(2)(d), while a Class III or IV application must include a copy of the label and the directions for use, under paragraphs 32(3)(g) and 32(4)(o). Health Canada states that, for those classes, it expects evidence that the directions meet the guidance's specifications, and it requests validation information showing that the recommended procedures will be effective when carried out in a hospital reprocessing department using equipment and supplies typically available there.
The third layer is the facility standard. CSA Z314:23, the second edition of the Canadian medical device reprocessing standard, supersedes the 2018 edition, and its scope explicitly does not address reprocessing of single-use or disposable medical devices. That exclusion is a useful boundary marker for buyers: a supplier citing Z314:23 to support a single-use reprocessing claim is citing a document that does not cover the question.
| Question | Canada | United States | International | What it means at the bench |
|---|---|---|---|---|
| What makes the instruction mandatory? | Regulations section 21(1)(i) and (j), with section 23 on language | Labelling is a premarket requirement; the reprocessing guidance describes how to formulate and scientifically validate the instructions | ISO 17664-1:2021 contractually or through regulatory adoption | A missing instruction is a labelling defect, not simply poor service |
| Which document gives the method? | 2011 guidance referencing ISO 17664, plus provincial facility standards | FDA guidance of 17 March 2015, Appendix E updated 9 June 2017 | ISO 17664-1 with ISO 14971 for the risk file | The method is harmonised; the wording of the obligation is not |
| What validation evidence is expected? | A summary on request, and validation information for Class III and IV submissions | Scientific validation as described in the guidance, including worst-case and soil considerations | Objective evidence for each claimed process | Ask for the summary before the first purchase, not after an inspection |
| Who checks the device family? | Grouping allowed where procedures are identical | Grouping accepted with justification in the submission | Family approach permitted with documented equivalence | A family claim needs an equivalence rationale you can read |
| What happens to single-use devices? | Facilities must not reprocess internally; no licensed reprocessors currently exist in Canada | Licensed third-party reprocessors exist under FDA oversight | Depends on jurisdiction | TIR12's single-use scope does not create a Canadian permission |
The pattern across the three columns is consistent: the technical content converges on ISO 17664, while the legal consequence diverges. That is why the same instruction can be adequate in one market and deficient in another, and why a Canadian buyer who receives a European or American instruction should look for the two items Canada adds, which are language availability on request and the storage-conditions statement.
What should a clinic ask before it buys?
Five questions, in this order, will separate a validated instruction from a document that merely looks complete.
- Show the validation summary, not the certificate. A certificate of quality management tells you the maker's system is audited; it does not tell you the cleaning method was tested against this device's hardest feature.
- Name one validated chemistry per step. An instruction that says "use a compatible enzymatic detergent" transfers the selection risk to the clinic. The 2011 guidance expects at least one example trade name per product type, which is the field that makes substitution decisions possible.
- Ask which challenge device was used, and what runs in your facility. This is where TIR31 meets daily practice, and where a mismatch quietly appears after a supplier changes a pouch or a load configuration.
- Ask for the drying step as a step. Method, duration and any lumen caveat, in the instruction rather than in a training slide.
- Ask for the storage statement. Special storage conditions are label content under the Regulations, and they are usually the first field to disappear when an instruction is condensed for a web page.
A buyer can also check the instruction against the packaging actually supplied. Pouches and reels carry process indicators and a write-on area because the packaging is the part of the sterile barrier the clinic handles, while a wrapped tray depends on autoclave indicator tape to show that the outside of the pack saw the process; whether the manufacturer validated that packaging is a separate question from whether the indicator changes colour. Our own product pages describe the pouch format, and the indicator class question is treated in the post-audit breakdown of a failed pouch labelling inspection.
The wider compliance frame, including how the facility side of these obligations is inspected in Ontario, sits in the sterilization compliance hub, and a monitoring programme that documents the sterilization step against a written instruction is described in steam quality testing and the three measured properties.


Sources
- AAMI TIR12:2020/(R)2023, Designing, testing, and labeling medical devices intended for processing by health care facilities
- ANSI Webstore: AAMI TIR12:2020 record
- ANSI: what TIR12:2020/(R2023) covers and the three processing objectives
- AAMI TIR31:2008, Process challenge devices/test packs for use in health care facilities
- ANSI Webstore: AAMI TIR31:2008 record
- AAMI TIR30:2011/(R)2016, compendium of cleaning processes, test methods and acceptance criteria
- ISO 17664-1:2021, information for the processing of critical and semi-critical medical devices
- ISO 14971:2019, application of risk management to medical devices
- ISO 11607-1, packaging for terminally sterilized medical devices
- Health Canada: guidance on information to be provided by manufacturers for the reprocessing and sterilization of reusable medical devices, 1 June 2011
- Medical Devices Regulations, SOR/98-282, sections 21 to 23 (labelling and language)
- Medical Devices Regulations, SOR/98-282, section 32 (licence applications)
- FDA: Reprocessing Medical Devices in Health Care Settings, Validation Methods and Labeling
- FDA: the same guidance as a single document, issued 17 March 2015
- CSA Group: CSA Z314:23, Canadian medical device reprocessing in all health care settings
- Public Health Ontario: provincial guidance on cleaning, disinfection and sterilization in all health care settings
- RCDSO: infection prevention and control standard of practice
- CliniEco Medical: sterilization monitoring collection
Reselling or buying for a facility? become a distributor for wholesale and multi-site ordering.
Related Reading
- ISO 17664 reprocessing instructions: what a clinic owes its auditor
- ISO 17664 for clinics and suppliers: the two audiences of one instruction
- Post-audit breakdown: why a four-chair Ontario clinic failed pouch labelling
Frequently Asked Questions
Is AAMI TIR12 a standard a device maker must follow?
No. It is a technical information report, a document class that AAMI approves for distribution through a technical committee and the Standards Board rather than through the formal consensus process used for standards. It is nevertheless the practical method most device makers use when they write reprocessing instructions, and regulators can expect an equivalent level of detail whether or not the report is cited.
Does TIR12 apply to single-use devices?
In its 2020 edition, yes, for devices that a health care facility processes before clinical use. That is a scope statement about the document, not a permission. Provincial guidance in Canada states that health care settings must not internally reprocess single-use equipment and devices, and that there are currently no licensed reprocessors in Canada, so a clinic cannot rely on TIR12's scope to justify reuse.
What is the difference between TIR12 and TIR31?
TIR12 is written for the device manufacturer and covers how to define, test and label the processing sequence. TIR31 is written for the facility and covers how to select and use process challenge devices, which are the objects that place a defined resistance in the sterilant's path. One produces the instruction; the other produces the routine challenge against it.
Which parts of the instruction does ISO 17664-1 require to be validated?
Every process the instruction identifies. The requirement is that the manufacturer shall validate each process that is identified in the information supplied with the device, and the validation must rest on objective evidence. In practice that means cleaning, disinfection, drying, inspection, packaging, sterilization and storage each need a supporting study, not a general statement of experience.
Do we need a French version of the instructions for use in Canada?
Section 23 of the Medical Devices Regulations requires the label information to be at least in English or French, and where the directions for use are supplied in only one official language at the time of sale, the manufacturer must make the other official language available as soon as possible at the purchaser's request. For devices sold to the general public, the listed label items must appear in both languages.
What should we do if a supplier cannot provide a validation summary?
Treat the instruction as unverified and record the gap in your supplier file. You can still use the device, because the labelling obligation sits with the manufacturer, but your own risk assessment should note that the processing steps have no documented basis you have seen. Ask again in writing, because the 2011 guidance expects the summary to be available on request from the purchaser.
CliniEco Medical supplies sterilization monitoring and infection control consumables in Canada under MDEL #35334. This article describes published standards and does not constitute regulatory, quality or legal advice; confirm the applicable edition and your own obligations with your supplier, your provincial regulator and your device reprocessing lead. Multi-site and institutional purchasing runs through wholesale accounts, questions about how a validated instruction maps onto your sterilizer go to a sterilization compliance specialist, and a five-pack of biological indicators for a trial load is available through the 24-hour biological indicator 25-pack.